6 completed, 1 not yet recruiting. 3 Phase 4, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 1, Not yet recruiting 1 |
Follow fluindione: new trials by email Literature Review of fluindione trials Research Report on fluindione
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome Vitamin K Antagonist - Drug, Anticoagulant Therapy Discontinuation - Antiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 234 | 2026-12-01 | 2026-10-15 |
| Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension Oral anticoagulant treatment - Pulmonary Arterial Hypertension | Completed | Centre Hospitalier Universitaire de Saint Etienne | 203 | 2017-07-05 | 2024-06-04 | |
| Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation Edoxaban, VKA-Based Regimen - Atrial Fibrillation | Phase 3 | Completed | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 632 | 2017-03-21 | 2019-09-23 |
| Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban, Vitamin K antagonist: warfarin, fluindione, acenocoumarol - Atrial Fibrillation | Completed | Assistance Publique - Hôpitaux de Paris | 159 | 2015-02-01 | 2022-03-29 | |
| Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy Vitamin K antagonist, Apixaban - Atrial Fibrillation | Phase 4 | Completed | Atrial Fibrillation Network | 676 | 2014-12-01 | 2017-10-20 |
| Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation Rivaroxaban, Fluindione, Warfarin - Permanent Atrial Fibrillation, Venous Thrombosis | Phase 4 | Completed | University Hospital, Angers | 51 | 2013-05-21 | 2019-11-07 |
| Anticoagulant Clinics and Vitamin K Antagonists Anticoagulant (warfarin, acenocoumarol, fluindione) - Blood Coagulation Disorders | Phase 4 | Completed | University Hospital, Toulouse | 1006 | 2003-02-01 | 2009-08-26 |
Atrial Fibrillation (3) · Antiphospholipid Syndrome (1) · Blood Coagulation Disorders (1) · Pulmonary Arterial Hypertension (1) · Pulmonary Embolism (1) · Thrombosis (1) · Venous Thrombosis (1)
Assistance Publique - Hôpitaux de Paris (2) · Atrial Fibrillation Network (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (1) · University Hospital, Angers (1) · University Hospital, Toulouse (1)
France (5) · Belgium (2) · Germany (2) · Italy (2) · Spain (2) · United Kingdom (2) · Austria (1) · Canada (1) · Czechia (1) · Denmark (1) · Hungary (1) · Netherlands (1) · Poland (1) · South Korea (1) · Taiwan (1)
Bernard Boneu, MD (1) · Florence Tubach, PhD (1) · Henri Boccalon, MD (1) · Laurent Bertoletti, PhD (1) · Patrick Mismetti, MD (1) · Paulus Kirchhof, Professor (1)
PMID 29663464, PMID 32725107, PMID 33249467, PMID 35135308, PMID 37897713
2016 (2), 2014 (1)